The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ILLUCCIX (Telix Pharmaceuticals (ANZ) Pty Ltd)
Product name
ILLUCCIX
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
Glu-urea-Lys(ahx)-hbed-CC
Registration type
EOI
Indication
for the selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.